Influvac® sub-unit Tetra provides active immunisation against four influenza virus strains: an A/(H1N1) strain, an A/(H3N2) strain, and two B strains (one from each lineage; B/(Victoria) and B/(Yamagata)).1
Influvac® sub-unit Tetra, manufactured according to the same process as trivalent influenza vaccine Influvac, induces humoral antibodies against the haemagglutinins1. These antibodies neutralise influenza viruses.1
Specific levels of hemagglutination-inhibition (HI) antibody titer post-vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza illness but the HI antibody titers have been used as a measure of vaccine activity.1
An immune response is generally obtained within 2 to 3 weeks. The duration of postvaccinal immunity to homologous strains or to strains closely related to the vaccine strains varies but is usually 6-12 months.1
- 1.Influvac® sub-unit Tetra Summary of Product Characteristics: Available at: https://www.medicines.org.uk/emc/product/9381/smpc. Last accessed November 2022
Viatris Connect is an online platform for UK health Professionals.
Across the website you will find news, blogs and product information.
Register to Viatris Connect today
Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.
REGISTER NOW